WHO WE ARE

We are a dual-listed (Euronext Brussels and NASDAQ: TIG) biopharmaceutical company focused on exploiting the anti-inflammatory properties of stem cells to develop novel therapies for serious medical conditions in areas of high unmet medical need.

19 January 2018

Transparency Information ( EN NL )

18 January 2018

Transparency notification
pursuant to Article 14 of the Law of May 2, 2007 ( ENNL )

UPCOMING EVENTS

  • INVESTORS AND PARTNERING
  • SCIENTIFIC AND OTHERS

SHARE PRICE

NASDAQ
41.96 USD
Change (%):
0.02 (0.05%)
BRU
1.72 EUR
Change (%):
-0.00 (-0.23%)


ABOUT US

CORPORATE VIDEO

CORPORATE PRESENTATION


FACT SHEET